--- type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/39995078.md" description: "$Sarepta Therap(SRPT.US) | π’πšπ«πžπ©π­πš: H.C. Wainwright reiterates π’πžπ₯π₯, maintains 𝐏𝐓 𝐚𝐭 $πŸ“Analyst sees rising efficacy risks from new Roche study, with limited upside and significant downside to core U.S. ELEVIDYS franchise.Source: Hardik Shah" datetime: "2026-04-17T11:17:30.000Z" locales: - [en](https://longbridge.com/en/topics/39995078.md) - [zh-CN](https://longbridge.com/zh-CN/topics/39995078.md) - [zh-HK](https://longbridge.com/zh-HK/topics/39995078.md) author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)" --- # $Sarepta Therap(SRPT.US) | π’πšπ«πžπ©π­πš: H.C. Wa… ### Related Stocks - [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md) - [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md) - [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)